secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001193125-23-276007
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Q3 net loss $47.7M; new CEO Mahoney; cash runway into 2026 after $185M placement
--------------------------------------------------------------------------------

- Net loss $47.7M vs $28.9M YoY; R&D $30.4M (+$8.3M) and G&A $20.9M (+$12.0M).
- Cash, equivalents & ST investments $313M at Sep 30; closed $185M private placement Nov 1 extending runway into 2026.
- Stephen Mahoney appointed President/CEO in Oct; new COO Thomas Beetham and CBO Shan Wu also hired.
- THRIVE (active TED) and THRIVE-2 (chronic) Phase 3 trials on track; topline mid-2024 and year-end 2024 respectively.
- Subcutaneous program selection by year-end 2023; Phase 1 data for VRDN-001/002/003 expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523276007/0001193125-23-276007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523276007/d85328d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-276007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer